PERFORM AND VALIDATE YOUR PROCEDURES WITH CONFIDENCE

A primary focus during the early stages of research and drug development is to minimize future risk. As such, protein binding studies are often necessary to determine a drug’s efficacy. While regulatory guidance exists concerning protein-binding studies, detailed guidelines on how to perform and validate the procedures does not. This is where Worldwide shines and can play a vital role in your drug development program.

WORLDWIDE CLINICAL TRIALS: YOUR EXPERIENCED PROTEIN-BINDING STUDY PARTNER

Worldwide’s wealth of experience executing protein-binding studies coupled with the application of larger capacity, automated formats delivers high-quality, timely data at excellent value. We can accommodate both in vitro and ex vivo protein-binding studies (from animal species to man) utilizing plasma or tissue homogenates. Our procedures include the following:

  • Automated processing
  • Custom-built equilibrium dialysis device (500 µL volume) or other commercial plate-based systems
  • Equilibrium dialysis
  • Radioactive or non-radioactive compounds
  • Ultracentrifugation
  • Ultrafiltration
  • Radio-labelled warfarin as a positive control
  • Fully validated, high sensitivity LC-MS assays
  • Standard Operating Procedures with QA oversight and review

AT WORLDWIDE, YOU ARE MORE THAN A MOLECULE

Are you ready to take your protein-binding study to the next level? Are you looking for a partner that can provide you with the operational excellence your program needs? Contact a Worldwide expert for support – no matter where you are on the path of drug development and research.

WORLDWIDE IS AN AWARD-WINNING, TOP-PERFORMING EARLY PHASE CRO

See how we rank amongst the world’s early phase contract research organizations.